1. Induction and transplant success with quadruplet NDMM regimen
2. Improved outcomes for induction and transplant with quadruplet NDMM therapy.
Accident – Death – Obituary News :
A recent case study presented by Stephanie L. Elkins, MD, Division Director at the School of Medicine, The University of Mississippi Medical Center, highlighted the complexities of treating a 54-year-old woman diagnosed with IgG-κmyeloma. The patient presented with several laboratory abnormalities, including low hemoglobin levels, high calcium levels, and monoclonal plasma cells in the bone marrow.
The patient’s diagnosis of R-ISS stage 2/R2-ISS stage 3 IgG-κmyeloma made her eligible for autologous stem cell transplant (ASCT). The discussion among the expert panel focused on the choice between triplet and quadruplet regimens for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Expert Insights
Chandar Bhimani, MD, highlighted the results of the PERSEUS and GRIFFIN trials, which demonstrated the superiority of quadruplet regimens in terms of progression-free survival (PFS) in transplant-eligible patients. Venu Madhav Konala, MD, emphasized the importance of minimal residual disease (MRD) negativity as an endpoint in treatment selection.
Stephanie L. Elkins, MD, acknowledged the data supporting quadruplet regimens but raised concerns about the long-term sustainability of using four drugs upfront. The panel also discussed the criteria for a successful treatment response post-induction therapy, with a consensus on achieving at least a very good partial response (VGPR) before considering transplant.
Transplant Considerations
Harish Madala, MD, highlighted the importance of achieving a VGPR post-induction therapy before considering transplant. Ethan Tolbert, MD, shared his approach of sending all eligible patients for transplant unless contraindicated due to age or health status.
Elkins reiterated the role of transplant in multiple myeloma treatment and emphasized the need for a minimum VGPR before proceeding with the procedure. The panel agreed that deeper responses were preferable but not always necessary for transplantation.
Overall, the expert panel provided valuable insights into the treatment decisions for patients with multiple myeloma, emphasizing the need for individualized care and considering factors such as response to induction therapy and eligibility for transplant.
References:
1. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301-313. doi:10.1056/NEJMoa2312054
2. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi:10.1182/blood.2020005288
.
– long-tailed keyword: Induction and transplant outcomes improve with quadruplet NDMM regimen
– long-tailed: Induction transplant outcomes improve quadruplet NDMM regimen.
